About: Duration of Antibody Responses after Severe Acute Respiratory Syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Duration of Antibody Responses after Severe Acute Respiratory Syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Duration of Antibody Responses after Severe Acute Respiratory Syndrome
Creator	Wang, Lin-Fa Liang, Guo-Dong Chang, Yi-Hua Lan, Tao Na, Dan-Yu Tian, Xiang-Yi Wang, Nai-Chang Wu, Li-Ping Zhang, Li-Yuan Zheng, Lei
source	Medline; PMC
abstract	Among 176 patients who had had severe acute respiratory syndrome (SARS), SARS-specific antibodies were maintained for an average of 2 years, and significant reduction of immunoglobulin G–positive percentage and titers occurred in the third year. Thus, SARS patients might be susceptible to reinfection >3 years after initial exposure.
has issue date	2007-10-01(xsd:dateTime)
bibo:doi	10.3201/eid1310.070576
bibo:pmid	18258008
has license	no-cc
sha1sum (hex)	2b554bfe12a457f1092ae7b12537e48cb3392f67
schema:url	https://doi.org/10.3201/eid1310.070576
resource representing a document's title	Duration of Antibody Responses after Severe Acute Respiratory Syndrome
has PubMed Central identifier	PMC2851497
has PubMed identifier	18258008
schema:publication	Emerg Infect Dis
resource representing a document's body	covid:2b554bfe12a457f1092ae7b12537e48cb3392f67#body_text
is schema:about of	covid:arg/2b554bfe12a457f1092ae7b12537e48cb3392f67 named entity 'susceptible' named entity 'severe acute respiratory syndrome (SARS)' named entity 'patients' named entity 'SARS' named entity 'Severe Acute Respiratory Syndrome' named entity 'negative control' named entity '1, 2' named entity 'SARS' named entity 'viruses' named entity 'IgG' named entity 'antigen' named entity 'immune responses' named entity 'immunoglobulin' named entity 'longitudinal study' named entity 'SARS-associated coronavirus' named entity 'World Health Organization' named entity 'IgG' named entity 'Biotechnology' named entity 'SARS' named entity 'IgM' named entity 'serum' named entity 'IgM' named entity 'positive control' named entity 'human coronaviruses' named entity 'OC43' named entity 'SARS' named entity 'SARS' named entity 'Beijing' named entity 'transmissible disease' named entity 'primary antibodies' named entity 'SARS-CoV' named entity 'Shanxi Province' named entity 'SARS' named entity 'antibodies' named entity 'antibodies' named entity 'coronavirus' named entity 'Serum samples' named entity 'serum samples' named entity 'Chicago' named entity 'symptom' named entity 'follow-up' named entity 'IgG' named entity 'IgG' named entity 'SARS-CoV' named entity '2, 3' named entity 'cross-species transmission' named entity 'infection' named entity 'IgM' named entity '21.4%' named entity 'IgM' named entity 'IgM' named entity 'IgG' named entity 'IgG' named entity 'antibodies' named entity 'Optical density' named entity 'serum samples' named entity 'Windows' named entity 'IgG' named entity 'IgG' named entity 'IgM' named entity 'incubation' named entity 'vaccine' named entity 'People's Republic of China' named entity 'IgG' named entity 'IgG' named entity 'lysate' named entity 'negative control' named entity 'Horseradish' named entity 'virus' named entity 'SARS' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software